Form 4: Kiniksa CFO Exercises Options, Sells Shares

Kiniksa Pharmaceuticals' Chief Financial Officer, Mark Ragosa, executed pre-planned transactions involving the exercise of stock options and subsequent sale of Class A Ordinary Shares.

Summary

• Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported transactions involving the company's Class A Ordinary Shares.
• On February 9, 2026, Mr. Ragosa exercised options to acquire 8,374 Class A Ordinary Shares at an exercise price of $12.97 per share.
• On the same date, he also exercised options to acquire 2,471 Class A Ordinary Shares at an exercise price of $16.9 per share.
• Following these exercises, Mr. Ragosa sold 9,114 Class A Ordinary Shares at a weighted average price of $42.85 per share, with prices ranging from $42.35 to $43.345.
• Additionally, he sold 8,731 Class A Ordinary Shares at a weighted average price of $43.72 per share, with prices ranging from $43.35 to $44.18.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan established on August 14, 2025.
• After these transactions, Mr. Ragosa's direct beneficial ownership of Class A Ordinary Shares stands at 12,086.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the pre-planned nature via a 10b5-1 plan mitigates any strong negative signal, suggesting personal financial management rather than a reaction to new company-specific information.

Positives

• The transactions demonstrate a profitable exercise of stock options by the CFO, with sale prices significantly higher than the exercise prices ($42.85 and $43.72 vs. $12.97 and $16.9).
• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and not reactive sale.

Negatives

• The net effect of the transactions was a reduction in the CFO's direct beneficial ownership of Class A Ordinary Shares by 7,000 shares (17,845 sold 10,845 acquired).
• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, potentially signaling a lack of confidence, although this is mitigated by the pre-planned nature.

Risks

• Potential negative investor sentiment due to insider selling, which could put downward pressure on the stock price.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that transactions by corporate insiders, particularly those executed under Rule 10b5-1 plans, are a common occurrence in the public markets. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing an affirmative defense against insider trading allegations and often reflecting personal financial planning rather than a direct signal about the company's immediate prospects.

Stakeholder Impact

• Shareholders may interpret the insider selling differently, potentially leading to varied sentiment regarding the stock.
• Employees and other stakeholders are unlikely to be directly impacted by this routine insider transaction.

Key Dates

Recommendation

While insider selling can sometimes be a negative signal, the execution under a pre-established 10b5-1 plan suggests a routine personal financial management decision rather than a reaction to new, adverse company information. Therefore, this Form 4 alone does not provide sufficient grounds for a strong buy or sell recommendation, warranting a 'hold' position while monitoring broader company performance and market trends.

Keywords

Kiniksa Pharmaceuticals, KNSA, Form 4, Insider Trading, Stock Options, CFO, Share Sale, 10b5-1 Plan, Executive Compensation